These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Valbenazine for the treatment of tardive dyskinesia. Seeberger LC; Hauser RA Expert Opin Pharmacother; 2017 Aug; 18(12):1279-1287. PubMed ID: 28699794 [TBL] [Abstract][Full Text] [Related]
27. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Chen JJ; Ondo WG; Dashtipour K; Swope DM Clin Ther; 2012 Jul; 34(7):1487-504. PubMed ID: 22749259 [TBL] [Abstract][Full Text] [Related]
28. Levetiracetam in tardive dyskinesia. Meco G; Fabrizio E; Epifanio A; Morgante F; Valente M; Vanacore N; Di Rosa AE; Morgante L Clin Neuropharmacol; 2006; 29(5):265-8. PubMed ID: 16960471 [TBL] [Abstract][Full Text] [Related]
29. Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review. Caroff SN; Aggarwal S; Yonan C J Comp Eff Res; 2018 Feb; 7(2):135-148. PubMed ID: 28965423 [TBL] [Abstract][Full Text] [Related]
30. Levetiracetam in tardive dyskinesia: an open label study. Konitsiotis S; Pappa S; Mantas C; Mavreas V Mov Disord; 2006 Aug; 21(8):1219-21. PubMed ID: 16637037 [TBL] [Abstract][Full Text] [Related]
31. Covert dyskinesia associated with aripiprazole: a case report and review of the literature. Moseley CN; Simpson-Khanna HA; Catalano G; Catalano MC Clin Neuropharmacol; 2013; 36(4):128-30. PubMed ID: 23860346 [TBL] [Abstract][Full Text] [Related]
32. Dopamine depleters in the treatment of hyperkinetic movement disorders. Jankovic J Expert Opin Pharmacother; 2016 Dec; 17(18):2461-2470. PubMed ID: 27819145 [TBL] [Abstract][Full Text] [Related]
33. Expanding phenomenologic heterogeneity of tardive syndromes: Time for an updated assessment tool. Bhidayasiri R; Kane JM; Frei KP; Caroff SN; Correll CU; Fahn S; Jankovic J; Hauser RA; Truong DD Parkinsonism Relat Disord; 2020 Aug; 77():141-145. PubMed ID: 32823151 [TBL] [Abstract][Full Text] [Related]
36. Loss of dopamine neuron terminals in antipsychotic-treated schizophrenia; relation to tardive dyskinesia. Seeman P; Tinazzi M Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jul; 44():178-83. PubMed ID: 23454261 [TBL] [Abstract][Full Text] [Related]
37. Successful Treatment of Severe Tardive Dyskinesia with Valbenazine, Including a Patient's Perspective. Josiassen RC; Filmyer DM; Gillean J; Shah SS; Dietterich TE; Shaughnessy RA Am J Case Rep; 2017 Nov; 18():1185-1189. PubMed ID: 29114100 [TBL] [Abstract][Full Text] [Related]
38. Valbenazine as the first and only approved treatment for adults with tardive dyskinesia. Sarva H; Henchcliffe C Expert Rev Clin Pharmacol; 2018 Mar; 11(3):209-217. PubMed ID: 29338466 [TBL] [Abstract][Full Text] [Related]
39. New and emerging treatments for symptomatic tardive dyskinesia. Rana AQ; Chaudry ZM; Blanchet PJ Drug Des Devel Ther; 2013; 7():1329-40. PubMed ID: 24235816 [TBL] [Abstract][Full Text] [Related]